FDA lowers Lunesta dose due to next-day drowsiness
The Food and Drug Administration is taking action based on a study that found Lunesta at recommended doses can cause problems with driving, memory and coordination up to 11 hours after first the drug is taken. Patients are often unaware that they are still drowsy.
Lunesta manufacturer Sunovion Pharmaceuticals will lower the starting dose of the tablet to 1 milligram from 2 milligrams. Patients can increase their dose, but should remember that higher doses are more likely to cause impairment the next day, according to the FDA.
Drowsiness is a side effect for all anti-insomnia drugs.
(Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)